Business Context and Reporting Period
This Form 8-K, dated January 31, 2024, reports on the extraordinary general meeting held by Semper Paratus Acquisition Corporation (a Cayman Islands exempted company) to approve a business combination with Tevogen Bio Inc. Upon consummation, Semper Paratus will redomesticate as a Delaware corporation, change its name to "Tevogen Bio Holdings Inc." (New Tevogen), and merge with Tevogen Bio. The filing covers the shareholder vote results and the immediate aftermath of the meeting.
Key Financial Metrics and Transaction Details
- Redemption Activity: Shareholders holding 1,432,457 Class A ordinary shares (Public Shares) exercised their right to redeem.
- Trust Account Withdrawal: Preliminary calculations indicate approximately $15.9 million will be removed from the Trust Account to pay redeeming shareholders.
- Redemption Price: Approximately $11.07 per Public Share.
- Voting Participation: 13,984,089 ordinary shares were represented at the meeting, establishing a quorum.
- Financial Performance: The filing does not provide revenue, profit, cash flow, or margin data for the combined entity or the target company.
Material Changes and Voting Results
All eight proposals presented to shareholders were approved. The voting results were consistent across all proposals, with 13,840,594 votes cast "For" and 143,495 votes cast "Against." There were no abstentions. Key approved proposals included:
- Business Combination: Approval of the merger agreement with Tevogen Bio.
- Domestication: Approval to deregister from the Cayman Islands and redomesticate in Delaware.
- Organizational Documents: Approval of new charter and bylaws, including increasing authorized common stock to 800,000,000 shares and preferred stock to 20,000,000 shares.
- Corporate Governance: Adoption of provisions regarding director removal, board size determination, and exclusive forum selection (Delaware Court of Chancery).
- Listing: Approval to list the combined company on The Nasdaq Stock Market under the symbols "TVGN" and "TVGNW."
- Compensation and Directors: Approval of the Omnibus Incentive Plan and the election of eight directors (Dr. Curtis Patton, Jeffrey Feike, Surendra Ajjarapu, Victor Sordillo, Dr. Keow Lin Goh, Dr. Ryan Saadi, and Susan Podlogar).
Outlook, Risks, and Contingencies
The Business Combination is expected to be consummated as soon as practicable following the satisfaction of remaining closing conditions, including Nasdaq listing approval. The filing includes extensive forward-looking statements and risk factors, noting that actual results may differ materially from expectations. Key risks identified include:
- Failure to complete the transaction in a timely manner or at all.
- Insufficient cash available post-redemption to fund operations.
- Tevogen Bio's limited operating history and lack of products approved for commercial sale.
- Regulatory risks associated with the FDA approval process for product candidates.
- Uncertainty regarding the ability to maintain patent protection for product candidates and the ExacTcell approach.
Investor Verification Checklist
- Verify the final redemption amount and per-share price once the Trust Account trustee completes calculations.
- Confirm the official listing approval of "TVGN" and "TVGNW" on The Nasdaq Stock Market.
- Review the definitive Proxy Statement/Prospectus for detailed financial projections and risk factors not included in this 8-K.
- Monitor the satisfaction of all closing conditions to ensure the transaction proceeds to consummation.
- Assess the capital structure of the new entity, specifically the 800 million authorized common shares and 20 million authorized preferred shares.